HOWARU® La-14®
Image credits: © IFF, Finland, 2021 (FESEM imaging VTT)
HOWARU® Lactobacillus acidophilus La-14® is a lactic acid bacterium of human origin that has been documented in over 115 scientific studies, including more than 35 clinical trial publications.
- ~ 59 preclinical publications
- 35+ clinical publications
La-14® CLINICAL STUDIES & PUBLICATIONS
Preclinical studies have shown La-14® can impact both the innate and the adaptive immune system.¹ These effects and antipathogenic activity are thought to be potential mechanisms behind the efficacy of La-14® combined with HN001™ for intimate health (HOWARU® Protect Prenatal+ and HOWARU® Feminine Health) as well as women’s health.² ³
In addition, these two strains together have been shown to support healthy vaginal colonization and microbiota through oral supplementation.⁴
Health Benefit Areas
Each strain’s health benefits are supported by recommended daily doses and peer-reviewed clinical studies.
Click on a Health Benefit to see more studies and learn more.
Supporting Daily Dose: 6B CFU HN001™, 9B CFU La-14®
Study Reference:
* Regional restrictions apply, please connect with your account manager for further information.
References: 1. Elawadli I et al.;Beneficial Microbes. 2014; 2. Bertuccini L et al.; Intl J Immunopathology Pharmacology. 2017; 3. Jang SE et al.;Nutrients. 2017; 4. De Alberti D et al.. Arch Gynecol Obstet. 2015